Search clinical trials for: Phentolamine Ophthalmic Solution 0.75%

Total 1832 results

Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Mydriasis | Dilation

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Dim Light Vision Disturbances

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) (MIRA-3)

Mydriasis | Dilation

United States
Ocuphire Pharma, Inc.

Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Night Vision Complaints | Decrease in Night Vision | Disturbance; Vision, Loss

United States
Ocuphire Pharma, Inc.

Completed

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects (MIRA-4)

Mydriasis | Dilation

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Presbyopia

United States
Ocuphire Pharma, Inc.

Active, not recruiting

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (VEGA-2)

Presbyopia

United States
Ocuphire Pharma, Inc.
Ophthalmic Consultants of Long Island

Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances (SNV)

Decrease in Night Vision | Disturbance; Vision, Loss

United States
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Ocular Hypertension | Open Angle Glaucoma

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Mydriasis | Dilation

United States
Aerie Pharmaceuticals

Completed

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Glaucoma

United States
Ocuphire Pharma, Inc.
Viatris Inc.

Recruiting

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2)

Mesopic Vision | Night Vision Loss

United States
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Allergan

Completed

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Conjunctivitis, Allergic

Korea, Republic of
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye

Dry Eye

China
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

Dry Eye

China
VivaVision Biotech, Inc

Recruiting

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Inflammation

United States
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Tarsus Pharmaceuticals, Inc.

Completed

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (Saturn-1)

Blepharitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Rigel Pharmaceuticals

Completed

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (DROPS)

Keratoconjunctivitis Sicca

United States
HanAll BioPharma Co., Ltd.
Daewoong Pharmaceutical Co. LTD.

Completed

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye (VELOS-3)

Dry Eye

United States
Tarsus Pharmaceuticals, Inc.

Recruiting

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers (Ariel)

Demodex Blepharitis

United States
Aurinia Pharmaceuticals Inc.

Completed

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)

Keratoconjunctivitis Sicca | Dry Eye Syndrome

United States
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Alcon Research

Completed

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Dry Eye
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Tarsus Pharmaceuticals, Inc.

Completed

A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Healthy

Canada
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Mitotech, SA
ORA, Inc.

Completed

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca

United States
Aerie Pharmaceuticals

Completed

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Ocular Hypertension | Open-angle Glaucoma
Aldeyra Therapeutics, Inc.

Completed

An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease

Dry Eye

Canada

3

Subscribe